NEOPHARMED GENTILI acquired by ARDIAN
Context
Ardian acquired a majority stake in Neopharmed Gentili from its founding parent company, Mediolanum Farmaceutici. The Del Bono family, founders of Mediolanum, retained a 20% minority stake in the business to ensure operational and clinical continuity. The transaction was structured to provide the group with the capital and global network necessary to transition from a national champion to an international specialty pharma platform. The investment thesis centered on using Neopharmed's robust Italian sales network as a foundation for an aggressive "buy-and-build" strategy, targeting both product portfolios and strategic corporate acquisitions across Europe.
NEOPHARMED GENTILI, which reported an EBITDA margin of [members only] in 2017, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Neopharmed Gentili is a leading Italian pharmaceutical company specialized in the development, production, and marketing of high-quality therapeutic treatments. It holds a dominant position in the Italian market for vascular, cardio-metabolic, and respiratory diseases, as well as anti-infectives and over-the-counter (OTC) products. The group acts as a key partner for global pharma giants like Merck and Teva, managing licensed portfolios alongside its own proprietary brands.
Ent. Value
€100–200M
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (EUR)
Similar deals in Life Sciences
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 04/2019 | EURAZEO | D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) | NETHERLANDS | Medical Devices |
| 12/2018 | MERCK & CO. | ANTELLIQ | FRANCE | Animal Health |
| 10/2018 | BRIDGEPOINT | HTL BIOTECHNOLOGY | FRANCE | CDMO |
| 10/2018 | ARDIAN | INULA GROUP | BELGIUM | Pharma & Biotech |
| 10/2018 | ASTORG | NEMERA | FRANCE | Medical Consumables |
| 10/2018 | GLANBIA | SLIMFAST | UNITED STATES | Nutrition & Dietary Supplements |
| 08/2018 | DENTRESSANGLE | ACTEON | FRANCE | Medical Devices |
| 05/2018 | NN | PARAGON MEDICAL | UNITED STATES | Medical Devices |
| 05/2018 | Zoetis | Abaxis | UNITED STATES | Diagnostic Equipment |
| 05/2018 | PERMIRA | CORIN GROUP | UNITED KINGDOM | Implants & Prosthetics |
Other operations with ARDIAN
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 07/2026 | ARDIAN | Munich Electrification | GERMANY | Batteries & EV Tech |
| 07/2026 | ARDIAN | Pflegia | GERMANY | Recruitment / Headhunting |
| 07/2026 | ARDIAN / EURAZEO / UBS | HR PATH | FRANCE | ERP, HR & Finance |
| 01/2026 | ARDIAN | IVB Wellness Lab | SPAIN | Nutrition & Dietary Supplements |
| 12/2025 | ARDIAN | Fermax | SPAIN | Safety & Security |
| 07/2025 | ARDIAN | Dovida | SWITZERLAND | Outpatient Care |
| 05/2025 | ARDIAN | MasterGrid | FRANCE | Electrical |
| 03/2025 | ARDIAN | AKUO | FRANCE | Renewables |
| 03/2025 | ARDIAN | DIOT-SIACI | FRANCE | Brokerage |
| 01/2025 | ARDIAN / EURAZEO / ASTORG | SYCLEF | FRANCE | HVAC (Heating/AC) |
REFERENCES
Revenue range: €100–200M
EBITDA range: €50–100M
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NEOPHARMED GENTILI by ARDIAN are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Acquirer: ardian